Peptide News Digest
Trend Report 10 min read

Can a Pharmacy in Your State Compound BPC-157 or TB-500? State Board Positions After the HHS Peptide Policy

HHS paused federal enforcement for six peptides, but states license the pharmacies. Kentucky said no on November 18; Utah adopted the federal terms.

Key points

  • HHS's October 30, 2026 policy (91 Fed. Reg. 68526) only pauses federal enforcement for BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c; it does not change state pharmacy law, and 503A pharmacies are licensed by states
  • The Kentucky Board of Pharmacy voted on November 18 to enforce 201 KAR 2:076 as written and deny waivers for all six peptides; its November 19 alert bars in-state and nonresident permit holders from compounding them or shipping them into Kentucky
  • Kentucky's rule allows only ingredients with a USP or NF monograph, components of FDA-approved drugs, or substances on FDA's bulks list, and the board says none of the six qualifies
  • Utah's Division of Professional Licensing said on October 30 it will exercise similar limited enforcement discretion, only when every HHS condition is met
  • Louisiana's Act 374, effective August 1, 2026, bars boards from prohibiting pharmacists who comply with section 503A from compounding peptides; whether the HHS policy satisfies that test is unsettled
  • Earlier medical board notices in Alabama, Mississippi and South Carolina ban prescribers from using research-grade or non-FDA-approved peptides; none had been clarified for the HHS policy as of November 20
  • Pharmacy boards in Massachusetts, Texas, Washington, California, Florida, Illinois, North Carolina, Georgia and Nevada had published nothing on the policy as of November 20; Arizona's board discussed it on November 9 with no published outcome found

Kentucky's board said no on November 18

On October 30, 2026, the U.S. Department of Health and Human Services (HHS) published a policy in the Federal Register (91 Fed. Reg. 68526) saying it does not intend to take enforcement action against a "State-licensed pharmacy, Federal facility, or licensed physician" that compounds drugs from six peptides: BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c. Our guide to the HHS policy covers the federal conditions. It does not settle whether a pharmacy can fill a prescription for one of them in your state.

Nineteen days after the notice, the Kentucky Board of Pharmacy gave its answer for Kentucky. At its November 18 meeting the board voted to enforce its compounding regulation, 201 KAR 2:076, as written and to refuse waivers for all six peptides. A compliance alert dated November 19 went to every resident and nonresident permit holder. It tells them not to compound any of the six for human use, not to dispense or ship them to patients or prescribers in Kentucky, and to pull existing stock out of active inventory. "The federal enforcement policy does not supersede Kentucky law and does not authorize compounding these substances in or into Kentucky," the alert says.

Violations count as unprofessional conduct under KRS 315.121, and the board can suspend, revoke, fine or otherwise restrict a license. The board said it will notify licensees if FDA adds any of the six to its 503A bulks list, so Kentucky's position could change later.

If you live in Kentucky, then, the board's position is that no pharmacy may compound BPC-157 or TB-500 for you or ship it to you, wherever the pharmacy is located. Everywhere else, the answer depends on your state's pharmacy board. Most of the boards we checked had published nothing about the policy as of November 20.

Why the federal pause leaves the decision with states

Pharmacies that compound under section 503A of the Federal Food, Drug, and Cosmetic Act fill prescriptions one patient at a time, and states license them. The HHS notice says as much when it names "State-licensed" pharmacies. HHS set aside only its own enforcement. It did not add the six peptides to FDA's 503A bulks list (the federal list of bulk ingredients pharmacies may compound with, at 21 CFR 216.23), and it did not change any state's pharmacy law.

The Federation of State Medical Boards (FSMB) made the same point in a November 10 FAQ, which the Alabama Board of Medical Examiners posted on its website on November 12. FSMB wrote that the policy "does not amend state medical or pharmacy practice acts, expand scope of practice, or direct state boards to suspend their own enforcement." It also noted the policy has no fixed end date and that HHS can revisit it if a safety or quality problem appears.

The sticking point in Kentucky is an ingredient rule. Section 3(5) of 201 KAR 2:076 allows a compounded drug for human use only if it meets a USP or National Formulary monograph (an official quality standard for a drug ingredient), is made from a component of an FDA-approved drug, or is made from a substance on FDA's bulks list. Those are the same three tests written into federal section 503A. The board said none of the six peptides passes any of them, so their use "in or into the Commonwealth has never been authorized," and the HHS policy creates no grace period.

In comments it filed with HHS on November 10, the Kentucky board noted that the gap between federal leniency and state law already existed. FDA lets pharmacies use substances in its "Category 1" while it reviews them, even though those substances are not on the bulks list either. The letter states the result for peptides plainly: "A Kentucky-permitted pharmacy that meets every condition of the policy may still violate Kentucky law." The letter says the same reading holds in other states whose law tracks section 503A. Kentucky is the only board we found that has applied it to the six peptides in writing.

Out-of-state pharmacies answer to your state's board

A telehealth peptide order can be filled by a pharmacy in one state and mailed to a patient in another. The pharmacy's home-state license is only part of the picture. The receiving state's rules also apply, and several boards say so directly.

Kentucky's alert covers nonresident permit holders, the out-of-state pharmacies licensed to ship into Kentucky, and says the shipping ban "includes preparations compounded by nonresident pharmacies permitted by the Board." Ohio requires a compounding pharmacy licensed there as a nonresident to name an Ohio-licensed pharmacist as the responsible person on its license and to meet Ohio's compounding standards for any drug it dispenses into Ohio. A notice from South Carolina's Board of Medical Examiners cites state law making it unlawful for facilities "within or outside of South Carolina" to sell or dispense drugs without a South Carolina Board of Pharmacy license. Mississippi's pharmacy, nursing and medical boards tell providers to buy only from entities the Mississippi Board of Pharmacy permits, and say unlicensed shippers can be reported.

So a pharmacy in Utah, where regulators have adopted the HHS terms, still may not ship BPC-157 to a patient in Kentucky.

Kentucky's comment letter also raised a problem of scale. Federal law caps a 503A pharmacy's out-of-state distribution at 5 percent of its prescriptions unless its home state has signed an agreement with FDA, but FDA has deferred enforcing that cap until it issues a final rule. Until then, the board wrote, "a single 503A pharmacy may ship compounded peptides nationwide in any quantity." The receiving state's board, the letter added, "may have little ability to inspect the out-of-state pharmacy or trace adverse events back to it."

The HHS policy does ask compounders to report the products they make, serious adverse events and quality problems "to FDA and to the States where the products are compounded and sent," as both Kentucky and FSMB quote it. Both groups pointed out that the policy does not name which state agency gets those reports, in what format, or how often.

Where the states we checked stood on November 20

We searched for published statements from state boards of pharmacy and medical boards between October 30 and November 20, 2026, and read each board's own document where one existed. The table lists only states where we found a board document, a state law, or a report quoting the board.

StateAgencyWhat it has publishedDate
KentuckyBoard of PharmacyEnforces 201 KAR 2:076 as written; no waivers for any of the six peptides; covers in-state and nonresident permit holders; violations can bring suspension, revocation or finesVote Nov. 18; alert Nov. 19, 2026
UtahDivision of Professional Licensing (DOPL)Will "exercise similar limited enforcement discretion in Utah, in strict accordance with the scope of this HHS interim policy," and only when each HHS condition is metOct. 30, 2026
LouisianaState law, summarized by the Board of PharmacyAct 374 bars licensing boards from prohibiting a pharmacist from compounding and dispensing peptides if the pharmacist complies with section 503A and USP-NF chapters; no board guidance on the HHS policy foundLaw effective Aug. 1, 2026
ArizonaBoard of PharmacyDiscussed the policy at a meeting, according to the Alliance for Pharmacy Compounding; we found no published outcome, and the board's website refused our requestsMeeting Nov. 9, 2026
OhioBoard of PharmacyGuidance says BPC-157 and other FDA Category 2 or 3 substances "cannot be compounded" under federal and state law; written before the HHS policy; no newer statement foundUpdated Dec. 8, 2025
AlabamaBoard of Medical ExaminersPosted the FSMB FAQ on the HHS policy without a new position of its own; its earlier notice bars physicians from compounding, administering or dispensing non-FDA-approved or research-grade peptidesFAQ posted Nov. 12; notice May 26, 2026
MississippiBoards of Pharmacy, Nursing and Medical Licensure (joint)No provider may compound, administer or dispense a non-FDA-approved or research-grade peptide; no update after the HHS policy foundAug. 19, 2026
South CarolinaBoard of Medical ExaminersPhysicians may not use research-grade or "FDA-ineligible" peptides; a footnote says Category 2 peptides should not be used in compounding; no update foundReported Aug. 18, 2026

We also checked the websites of the pharmacy boards in Massachusetts, Texas, Washington, California, Florida, Illinois, North Carolina, Georgia and Nevada. None had published anything on the HHS peptide policy as of November 20. Massachusetts' agenda for its November 5 meeting, dated before HHS released the policy, had no peptide item. Washington's November 5 commission agenda and meeting packet had none, and neither did the Texas board's summary of its November 3 meeting. A board that has said nothing still enforces its own compounding rules, and we did not review each of these states' ingredient regulations.

Louisiana is the hardest case to read. Its law protects pharmacists who compound peptides in compliance with federal section 503A. Whether compounding under the HHS policy counts as 503A compliance is unsettled. FSMB's FAQ told boards they should not assume a state-law requirement for 503A compliance "is met merely because a compounder follows the HHS enforcement policy," since the policy is a decision not to enforce rather than a change to the statute. The Louisiana Board of Pharmacy had not addressed the question publicly as of November 20.

Medical board warnings written before the policy

Alabama and South Carolina acted through their medical boards, which license prescribers, and Mississippi's statement came jointly from its medical, nursing and pharmacy boards. These notices came months before the HHS policy and were aimed at "research-grade" vials sold online. Alabama's Board of Medical Examiners issued its notice on May 26, 2026. Mississippi's three licensing boards issued a joint statement on August 19. South Carolina's board posted a similar notice that the American Med Spa Association reported on August 18.

All three say a patient consent form labeling a product "research-grade" does not shield a provider from liability. Alabama and Mississippi word their bans to cover any "non-FDA approved" peptide, and BPC-157 compounded under the HHS policy is still not FDA-approved. None of the three boards has said how its notice applies to a pharmacy-compounded product made under the federal conditions. FSMB suggested that boards "review existing peptide notices to determine whether clarification is needed." We found no such clarification as of November 20.

These notices matter even where a pharmacy is willing to fill the order, because the clinician who writes it answers to a medical board. The HHS policy also covers physicians who compound in their own offices. FSMB wrote that a physician would have to meet every federal condition and "separately confirm that state law permits the activity."

Ohio's pharmacy board took a hard line on clinics before any of this. Its guidance, last updated December 8, 2025, says the board had summarily suspended more than 30 clinics and medical spas since the start of 2025, and lists BPC-157 among substances that cannot be compounded. That guidance was written while BPC-157 sat in FDA's Category 2, which ended in April 2026. The board's homepage showed no newer statement on peptides as of November 20.

The safety record Kentucky cited

Kentucky did more than cite its rule. The alert tells pharmacists to call prescribers and explain FDA's safety concerns: all six peptides were in FDA's Category 2, a list of bulk substances that raise significant safety risks, from September 2023 to April 2026, and FDA's drug reviewers recommended against adding them to the bulks list because of insufficient human safety data, potential impurities and the risk of immune reactions. Pharmacists are told to give patients the same information and to warn them against products sold as "research use only." (Our explainer on research-use-only labels covers why those vials are a separate problem.)

The board's November 10 letter to HHS added detail. It said the six peptides left Category 2 because their nominations were withdrawn, "not because FDA found the risks resolved." It also summarized FDA's July 24 advisory committee presentation on Epitalon and Semax as citing poor physical and chemical characterization, insufficient human safety data and immunogenicity risk, along with a possible long-term cancer concern for Epitalon and abuse and bleeding signals for Semax. The committee voted to recommend all six anyway; our article on the PCAC vote has the tallies.

Those are FDA reviewers' concerns as Kentucky describes them. They describe gaps in the safety record rather than documented harm in patients, and human data on all six peptides remain thin for safety and for benefit alike.

Questions to ask a pharmacy or telehealth company

None of this tells you whether a peptide is right for you, and this article gives no dosing advice. It can help you check whether a legal supply exists where you live before you pay for a consultation.

Start with geography. Ask which pharmacy will compound the product and what state it is in. Then ask whether that pharmacy is licensed, or holds a nonresident permit, in the state where you live, and check the answer on your state board of pharmacy's license lookup. Ask which state's rules the company is following for your order. If you live in Kentucky, all six peptides are off the table for now.

Then ask about the product itself. The HHS policy covers single-ingredient products only, made from a bulk substance whose original manufacturer is registered with FDA and backed by a certificate of analysis. A blend such as BPC-157 with TB-500 falls outside it. Ask whether the ingredient is on any federal list (none of the six is on the 503A bulks list today) and whether the pharmacy can show you the manufacturer and testing documents. Our guide to evaluating a compounding pharmacy lists what a real certificate of analysis contains. Kentucky's alert tells pharmacists never to compound with anything labeled "research use only" or "not for human use," and you should treat such a vial as outside the pharmacy system altogether.

Hims & Hers said on November 18 that it will offer five compounded peptide and longevity formulations through its Peptides+ platform and plans to add BPC-157 and TB-500 over time, CNBC reported. The company says its products come from pharmacies "licensed and inspected by state boards of pharmacy." That statement does not say which states will be able to receive BPC-157 or TB-500, so ask before you sign up. For the wider federal picture, see our 2026 overview of peptide legality.

Updates and corrections

No corrections yet. We will add state positions as boards publish them.

Limitations

  • We checked board websites and documents for 17 states and searched news and trade coverage for others; we did not survey all 50 states, and a board can change its position at any time
  • For states marked as having published nothing, we reviewed the board's website and, where noted, recent meeting agendas; a board may have communicated with licensees through channels we could not see, such as email bulletins
  • Arizona's board website returned access errors, so its November 9 discussion is known only from the Alliance for Pharmacy Compounding's account
  • We could not open the HHS appendix that lists the full policy conditions; quotes of the reporting condition come from the Kentucky board's comment letter and the FSMB FAQ
  • We did not read every state's compounding regulation; states whose ingredient rules mirror section 503A could reach Kentucky's conclusion without saying so publicly
  • Nothing here is legal or medical advice; ask the pharmacy, your prescriber, or your state board about your situation

Citations

  1. 1.
  2. 2.
  3. 3.
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526)
    regulatory Federal Register, U.S. Department of Health and Human Services 2026
  4. 4.
    FAQs: Department of Health and Human Services (HHS) Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances
    organization Federation of State Medical Boards, posted by the Alabama Board of Medical Examiners 2026
  5. 5.
  6. 6.
    Peptide Enforcement Discretion Policy
    regulatory Utah Division of Professional Licensing 2026
  7. 7.
    Bulletin 26-01: New Laws from the 2026 Regular Session
    regulatory Louisiana Board of Pharmacy 2026
  8. 8.
    One federal policy, many potential state responses
    organization Alliance for Pharmacy Compounding 2026
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
    Joint Statement Concerning the Prescribing of Non-FDA Approved (Research-Grade) Peptides
    regulatory Mississippi Board of Nursing, Board of Pharmacy, and State Board of Medical Licensure 2026
  14. 14.
  15. 15.
  16. 16.
    Board of Registration in Pharmacy Meeting Agenda, November 5, 2026
    regulatory Massachusetts Board of Registration in Pharmacy 2026
  17. 17.
    Pharmacy Quality Assurance Commission, November 5, 2026 Business Meeting Agenda
    regulatory Washington State Department of Health 2026
  18. 18.

Peptides in this article

Full peptide profiles with evidence levels, dosing data, and safety notes live on peptidelist.org.

Related insights